目的：对视功能损害眼病患者生存质量量表(The quality of life scale which measures the quality of life for Chinese patients with visual impairment，SQOL-DV1)应用于甲状腺相关眼病(thyroid associated ophthalmopathy， TAO)患者生活质量评价进行效度、信度和反应度检验。

方法：应用SQOL-DV1量表对39例TAO患者和31例正常对照组进行调查。分析该量表能否准确有效评估TAO患者的生活质量。

结果：效度分析：(1)内容效度检验各个分项得分之间的相关系数0.62～0.80(P=0.00)，各个分项得分与量表总得分的相关系数0.88～0.89(P=0.00)。(2)区分效度检验TAO患者组在症状与视功能、身体机能、社会活动、精神心理各分项得分及量表总分上均低于正常对照组(P=0.00)， 治疗后TAO患者量表各分项得分及总得分提高(P<0.05)。信度分析：(1)重测信度。量表重复测量相关系数达到0.913(P=0.00)。(2)克朗巴赫系数为0.944。反应度分析：效应大小统计量(ES)为0.88。

结论：SQOL-DV1量表是评估TAO患者生活质量的一种有效、可信的工具，可用于临床上TAO患者生活质量的测量和相关研究。

AIM:To evaluate the validity, reliability and responsiveness of the quality of life scale which measures the quality of life for Chinese patients with visual impairment(SQOL-DV1)when it was used to assess the quality of life(QOL)in thyroid associated ophthalmopathy(TAO)patients.

METHODS:SQOL-DV1 was used to evaluate the QOL of 39 cases with TAO and 31 healthy people as the control group, and then it was analyzed that if the scale can be accurately and effectively assess the quality of life of the TAO patients.

RESULTS:Validity analysis: 1. content validity test. The correlation coefficient between each sub-score was about 0.62 - 0.80(P= 0.00), the correlation coefficient between sub-score and total score was about 0.88-0.89(P= 0.00). 2. Discriminant validity test. The degree scores in patients with TAO were lower than the control group in symptoms and visual function, physical function, social activities, spiritual and psychological of the sub-item scores and scale's total scores(P<0.05). Quality of life scale scores were significantly increased by the treatment(P<0.05). Reliability analysis: 1.The test-retest reliability. The correlation coefficient of repeated measurements was about 0.913(P= 0.00). 2. The Cronbach coefficient was 0.944. Reaction analysis: Effect size statistics(ES)was 0.88.

CONCLUSION: SQOL-DV1 scale is an effective, credible tool to assess the quality of life of the TAO Patients. It can be used for the measurement of quality of life of the TAO Patients in the clinical and related research.